课题基金 / 基金详情

METHYLPHENIDATE USE TO IMPROVE CLINICAL OUTCOMES IN GERIATRIC DEPRESSION

METHYLPHENIDATE USE TO IMPROVE CLINICAL OUTCOMES IN GERIATRIC DEPRESSION
使用哌醋甲酯改善老年抑郁症的临床结果
批准号:
7951593
负责人:
Helen Lavretsky
金额:
$1.03万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-04-01 至 2009-11-30

项目摘要

项目成果

Helen Lavretsky的其他基金

相似基金

相关文献

中文摘要
翻译
这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金, 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 目的:确定西酞普兰或安慰剂联合应用时,mph对老年抑郁症患者的临床和认知特征的影响,并与西酞普兰联合安慰剂进行比较。
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. To determine the effects of MPH on the clinical and cognitive features of late-life depression when it is used in combination with either citalopram or with placebo, and compared to citalopram combined with placebo.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Remote Tai Chi for Knee Osteoarthritis: an Embedded Pragmatic Trial
  • 批准号:
    10649920
  • 项目类别:
  • 资助金额:
    $91.17万
  • 财政年份:
    2023
  • 负责人:
    Helen Lavretsky
  • 依托单位:
EFFECTS OF VULNERABILITY AND RESILIENCY ON BRAIN HEALTH DURING THE MID-TO-LATE-LIFE TRANSITION
  • 批准号:
    10673904
  • 项目类别:
  • 资助金额:
    $23.22万
  • 财政年份:
    2021
  • 负责人:
    Helen Lavretsky
  • 依托单位:
4/5 Neurocognitive and neuroimaging biomarkers: predicting progression towards dementia in late-life depression
4/5 Neurocognitive and neuroimaging biomarkers: predicting progression towards dementia in late-life depression
国内基金
海外基金
Molecular Interaction Reconstruction of Rheumatoid Arthritis Therapies Using Clinical Data